当前位置:
X-MOL 学术
›
J. Hepatol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
WED-389 Pharmacokinetics and safety of the monoclonal antibody tobevibart (VIR-3434) administered as monotherapy or in combination with the small interfering RNA elebsiran (VIR-2218) in cirrhotic participants with mild hepatic impairment
Journal of Hepatology ( IF 26.8 ) Pub Date : 2024-06-08 , DOI: 10.1016/s0168-8278(24)02251-7 Li Wang , Sneha Gupta , Michael A. Chattergoon , Asma El-zailik , Cheng Huang , George Hristopoulos , Maribel Reyes
中文翻译:
WED-389 单克隆抗体托贝巴特 (VIR-3434) 作为单一疗法或与小干扰 RNA elebsiran (VIR-2218) 联合用药在患有轻度肝功能损害的肝硬化参与者中的药代动力学和安全性
更新日期:2024-06-08
Journal of Hepatology ( IF 26.8 ) Pub Date : 2024-06-08 , DOI: 10.1016/s0168-8278(24)02251-7 Li Wang , Sneha Gupta , Michael A. Chattergoon , Asma El-zailik , Cheng Huang , George Hristopoulos , Maribel Reyes
中文翻译:
WED-389 单克隆抗体托贝巴特 (VIR-3434) 作为单一疗法或与小干扰 RNA elebsiran (VIR-2218) 联合用药在患有轻度肝功能损害的肝硬化参与者中的药代动力学和安全性